Abstract: A mirror, a mirror substrate, a method for producing are provided. The mirror substrate is made of a material having a coefficient of mean linear thermal expansion of less than or equal to 1*10?6/K. The mirror substrate includes at least one feature selected from a group consisting of: a ratio of a lateral dimension to a maximum thickness of at least 100, a ratio of the lateral dimension to the maximum thickness of at least 150, a ratio of the lateral dimension to the maximum thickness of at least 200, a ratio of the lateral dimension to the maximum thickness of at least 300, a weight per unit area of 100 kg/m2 or less, a weight per unit area of 50 kg/m2 or less, a weight per unit area of 30 kg/m2 or less, a weight per unit area of 15 kg/m2 or less, a mirror surface with a roughness (Ra) of at most 3.5 ?m, and a mirror surface with a roughness (Ra) of less than 1.2 ?m.

Abstract: A mirror substrate is made of a material having a coefficient of mean linear thermal expansion of less than or equal to 1*10?6/K. The mirror substrate includes at least one of: a ratio of a lateral dimension to a maximum thickness of at least 100,, a weight per unit area of 100 kg/m2 or less,, and a mirror surface with a roughness (Ra) of at most 3.5 ?m.

Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: A compound or a pharmaceutically acceptable salt thereof of formula (I): (A)-x1-(B)-x2-(C), wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x1 is a spacer covalently connecting (A) and (B); x2 is a spacer or a chemical single bond connecting (B) and (C); wherein (C) has the formula wherein R1 to R4, R9, a, b, Y and X1 to X4 have the meaning as indicated in the claims and description. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.

Abstract: A device includes a first supply unit, which is connectable via a first switch element to a first consumer, a second supply unit, which is connectable via a second switch element and via one or more electric delimitation elements to the first consumer, and a third switch element, which is configured to bridge the one or more electric delimitation elements. A control unit is configured to cause the first switch element to close, and the second and third switch elements to open, in normal operation. The control unit is further configured to detect that a first supply voltage at the first supply unit has reached or fallen below a voltage threshold value, and in response causes first the second switch element to close, then the first switch element to open, and then the third switch element to close, such that the first consumer is coupled to the second supply unit.

Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , t ? i ? s ? s ? u ? e = C t ? mAb , tissue , det . C tissue , sample - C refmAb , tissue , det . C tissue , sample C refmAb , plasma , det . * C tmAb , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.

Abstract: A system includes a core drill and an automatic feed device. The core drill has a human machine interface (HMI) for controlling the core drill and the automatic feed device. A menu navigation of the HMI is automatically controllable in dependence on an operating state of the core drill or the automatic feed device. The menu navigation includes menu pages where the menu pages are displayable in dependence on the operating state of the core drill or the automatic feed device such that the menu navigation is controllable automatically depending on the operating state of the core drill or the automatic feed device.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced by applying an inert reference antibody that does not penetrate into said tissue, whereby the inert reference antibody is administered 2 to 10 minutes prior to obtaining the tissue and blood sample.

Abstract: Herein is reported a method for determining free antigen of an antibody in an undiluted serum sample comprising the steps of a) applying the undiluted sample to a solid phase on which a capture antibody has been immobilized to form a capture antibody-antigen complex, wherein the capture antibody competes with the antibody for binding to a first epitope on the antigen, b) applying to the solid phase a tracer antibody to form a capture antibody-antigen-tracer antibody complex, wherein the tracer antibody specifically binds to a second epitope on the antigen, wherein the epitope of the tracer antibody is not overlapping with the epitope of the capture antibody on the antigen, and c) determining the free antigen of the antibody by determining the tracer antibody in the capture antibody-antigen-tracer antibody complex.

Abstract: A power tool for processing a substrate, the power tool being designed for analyzing a composition of the substrate and including at least one recorder for recording an operating parameter of the power tool. A method for analyzing a composition of a substrate that is being processed by a proposed power tool is also provided. The analysis of the composition of the substrate takes place on the basis of the at least one recorded operating parameter which is recorded with the recording means, the analysis being performed in the power tool itself and during its operation.

Abstract: A method for releasing a screw connection between a core drilling device and a drill bit, wherein the screw connection is released by application of torque spikes to the drive shaft of the core drilling device, these torque spikes coming into effect when the drive shaft is driven counter to the actual drilling direction of the core drilling device. A core drilling device with which the proposed method can be carried out is also provided. To this end, the core drilling device includes a drive shaft to which torque spikes can be applied, wherein the drive shaft can be driven in a drilling direction and a second direction of rotation which is opposite to the drilling direction.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.

Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: A compound or a pharmaceutically acceptable salt thereof of formula (I): (A)-x1-(B)-x2-(C), wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x1 is a spacer covalently connecting (A) and (B); x2 is a spacer or a chemical single bond connecting (B) and (C); wherein (C) has the formula wherein R1 to R4, R9, a, b, Y and X1 to X4 have the meaning as indicated in the claims and description. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition.

Abstract: The present invention relates to a compound of a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x1 is a spacer or a chemical single bond covalently connecting (A) to the rest of the molecule; x2 is a spacer or a chemical single bond covalently connecting (C) to the rest of the molecule. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition.

Abstract: An electric/electronic architecture for a motor vehicle includes an electronic computing device for communicating with at least one actuator of the motor vehicle. The electric/electronic architecture has an interface controller which is contacted by at least one sensor device of the motor vehicle and the electronic computing device, wherein the at least one actuator directly communicates with the electronic computing device, and the at least one sensor device directly communicates with the interface controller.

Abstract: A method for operating an internal combustion engine. The method includes: operating the internal combustion engine including a lambda regulation, which sets a fuel quantity to be supplied in accordance with a predefined setpoint lambda value, at preset times, carrying out a filter cleaning operation for a fuel tank ventilation, as a function of the presence of a release condition of the internal combustion engine, carrying out an adaptation of the lambda regulation by adapting at least one adaptation parameter as a function of operating variables of the internal combustion engine, at active filter cleaning operation and upon the presence of the release condition, operating variables which are required to carry out the adaptation of the lambda regulation being recorded, at deactivated filter cleaning operation and presence of the release condition, the adaptation of the lambda regulation being carried out as a function of the recorded operating variables.